Projezik

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Projezik

What is Projezik? A Foundational Overview

Property Description
Active ingredient Flurbiprofen
Form Oral tablet, solution
Pharmacological class Nonsteroidal Anti-inflammatory Drug (NSAID)
Common use Symptomatic relief of pain, inflammation, and fever
Origin Synthetic, propionic acid derivative

1. What Type of Medicine is Projezik? (Identity and Class)

Projezik is a prescription medicinal product containing the single active compound Flurbiprofen (C₁₅H₁₃FO₂), which is classified as a Nonsteroidal Anti-inflammatory Drug (NSAID). This medicine is a synthetic compound derived from propionic acid, placing it chemically alongside other established systemic anti-inflammatory agents. Flurbiprofen is intended for systemic action throughout the body, typically delivered in the pharmaceutical form of an oral tablet.

The classification as an NSAID establishes the drug's role in modulating the body's inflammatory response. Flurbiprofen is recognized within the propionic acid derivative class of NSAIDs, noting its systemic function. This chemical structure, which is clinically recognized for its potent anti-inflammatory properties, dictates its specific systemic activity and distinguishes it from simple analgesic-only medications.


2. General Purpose: Analgesic and Anti-inflammatory Action

The general purpose of Projezik is to provide symptomatic relief from issues associated with the inflammatory cascade, specifically pain, inflammation, and fever. The active ingredient, Flurbiprofen, exhibits three simultaneous properties: it functions as an analgesic (pain-relieving), an anti-inflammatory agent (swelling-reducing), and an antipyretic (fever-reducing).

The established use of Flurbiprofen relates to its effectiveness in relieving common pain and inflammatory symptoms. The medicine provides a method for easing discomfort and reducing swelling linked to inflammation, such as the temporary discomfort experienced during certain acute musculoskeletal events. This therapeutic action is achieved through the drug's ability to inhibit the synthesis of prostaglandins, assisting in the resolution of discomfort and elevated body temperature.

Regulatory References

  1. National Institutes of Health (NIH)

What side effects are possible with Projezik?

Possible Side Effects and Safety Information

Projezik (Flurbiprofen) is a nonsteroidal anti-inflammatory drug (NSAID) with important safety considerations, particularly regarding cardiovascular and gastrointestinal risks. The drug label includes prominent warnings about potential serious, sometimes fatal, events.

Serious and Clinically Significant Risks

  • Cardiovascular Thrombotic Events: Flurbiprofen may increase the risk of serious, life-threatening cardiovascular events, including myocardial infarction (heart attack) and stroke. This risk may begin early in treatment and may be greater with long-term use and in individuals with pre-existing heart disease or associated risk factors. It is contraindicated for use after Coronary Artery Bypass Graft (CABG) surgery.
  • Gastrointestinal Adverse Events: The medication carries a risk of serious gastrointestinal adverse events, such as bleeding, ulceration, and perforation of the stomach or intestines. These can occur without warning symptoms and may be fatal. Elderly patients and those with a prior history of peptic ulcer disease or GI bleeding are at the greatest risk.
  • Severe Reactions: Serious skin reactions, including Stevens-Johnson syndrome (SJS) and Toxic Epidermal Necrolysis (TEN), along with anaphylactic reactions and severe hepatotoxicity (liver injury), have been reported and require immediate medical attention.

Common Side Effects

The most frequently reported adverse reactions typically involve the gastrointestinal system and general effects, including:

  • Abdominal pain
  • Dyspepsia (indigestion)
  • Nausea
  • Diarrhea
  • Constipation
  • Headache
  • Fluid retention (edema)

Population-Specific Precautions

Caution is advised for specific populations. The elderly are at an increased risk for serious GI bleeding, cardiovascular events, and kidney-related side effects. The use of Flurbiprofen should be avoided in pregnant women starting at 30 weeks of gestation due to the risk of fetal harm. Patients with pre-existing conditions such as heart failure, hypertension, and asthma (especially aspirin-sensitive asthma) require careful monitoring.

Overdose and Emergency Response

Overdose and when to seek help

Acute over-exposure to Projezik, a nonsteroidal anti-inflammatory drug (NSAID), is officially documented to present with specific clinical manifestations. These include gastrointestinal symptoms such as nausea, vomiting, stomach pain, and heartburn. Central nervous system effects are also common and may include drowsiness, dizziness, confusion, or a change in consciousness, potentially progressing to coma.

The regulatory profile highlights the risk of severe, life-threatening outcomes. Documented complications include major gastrointestinal bleeding, ulceration, and perforation. Systemic events such as convulsions, acute renal failure, and metabolic acidosis are also associated with severe over-exposure. Elderly patients and individuals with pre-existing renal or hepatic impairment are noted to be at an increased risk for these severe complications.

Immediate medical attention is required for any suspected overdose. Regulatory documents mandate contacting emergency services or a poison control helpline if the person has collapsed, had a seizure, is experiencing trouble breathing, or cannot be awakened. Treatment is strictly symptomatic and supportive, as regulatory labeling states no specific antidote is known for Flurbiprofen overdose. Supportive procedures, such as gastric lavage or activated charcoal administration, may be utilized by medical professionals.

Therapeutic Uses of Projezik

What Projezik Treats — Main Uses and Benefits

Projezik is commonly used to provide symptomatic relief across therapeutic domains marked by pain, stiffness, and swelling. It is applied in contexts where additional symptomatic support is needed, and may help patients cope more steadily with symptom fluctuations. The medication is indicated for the symptomatic management of pain, tenderness, and stiffness associated with inflammatory conditions.

The medication is relevant for managing symptoms associated with chronic joint conditions such as rheumatoid arthritis and osteoarthritis, acute events like muscle strains and dental pain, and specific discomforts such as menstrual cramping (dysmenorrhea). In these situations, Projezik supports patients by easing the overall symptom burden, which contributes to improved day-to-day comfort and relates to the maintenance of functional stability.

“Projezik may be part of symptomatic management when joint pain and stiffness create noticeable interference with daily comfort.”

Symptomatic Support Focus
Commonly used for: Conditions presenting with systemic or localized discomfort and inflammatory or irritative states.

Regulatory References

  1. NIH MedlinePlus Drug Information on Flurbiprofen

Eligibility and Restrictions for Use

Projezik (flurbiprofen) is a nonsteroidal anti-inflammatory drug (NSAID) and is strictly contraindicated for several populations, based on official regulatory labeling.

Contraindicated Populations

  • Patients with a known hypersensitivity to flurbiprofen or any component of the drug.
  • Patients who have experienced asthma, hives (urticaria), or other allergic-type reactions after taking aspirin or other NSAIDs.
  • Patients in the setting of coronary artery bypass graft (CABG) surgery.

Eligibility-Related Warnings and Restrictions

  • Pregnancy (Late Term): The medicine must be avoided at or after 30 weeks gestation due to risks to the fetus (premature closure of the fetal ductus arteriosus and renal dysfunction). Use should be limited between 20 and 30 weeks of pregnancy.
  • Pediatric Use: Safety and efficacy have not been established in the pediatric population (children under 18).
  • Advanced Conditions: Use is not recommended in patients with severe heart failure or advanced renal disease unless the prescribing healthcare provider determines the benefits outweigh the risks.
  • Pre-existing Conditions: Caution and close monitoring are necessary for patients with fluid retention, hypertension, a recent heart attack, or a history of stomach ulcers/bleeding.

What should I know about interactions with other medicines?

Projezik (Flurbiprofen) interactions are documented by regulatory agencies, reflecting its Nonsteroidal Anti-inflammatory Drug (NSAID) classification.

Co-administration with other NSAIDs, including COX-2 selective inhibitors and high-dose salicylates, is formally restricted due to the documented risk of serious gastrointestinal toxicity. Use with alcohol is also prohibited due to the increased potential for mucosal bleeding. Timing separation is required for Mifepristone; Projezik should not be used for 8–12 days following its administration to prevent the reduction of its effect.

Regarding drug exposure, Flurbiprofen is primarily metabolized by the CYP2C9 enzyme. This pathway is relevant for individuals who are known poor CYP2C9 metabolizers, as they exhibit increased systemic exposure. Co-administration may also reduce the renal clearance of Lithium and Methotrexate, potentially leading to elevated plasma concentrations of these substances.

Pharmacodynamic constraints apply to agents that increase bleeding risk, such as Anticoagulants, Anti-platelet Agents, and SSRIs. Furthermore, Flurbiprofen may diminish the antihypertensive effect of ACE Inhibitors and ARBs and reduce the natriuretic effect of diuretics. An increased risk of renal deterioration is specifically noted in elderly or volume-depleted patients when these combinations are used.

Mechanism of Action

Projezik (Flurbiprofen) executes a molecular and systemic adjustment within the body's physiological signaling pathways. Its mechanism is centered on modulating the production and effect of key chemical mediators.


u1f52c Core Mechanism: Inhibition of Prostaglandin Synthesis

Projezik acts as a non-selective inhibitor of the Cyclooxygenase (COX) enzymes, specifically u1d34au1d34cu1d34d-u1d7d9 and u1d34au1d34cu1d34d-u1d7da. By blocking the enzymatic step that converts arachidonic acid into prostaglandins, the drug initiates a cascade that suppresses the synthesis of mediators that drive vasodilation and nociceptor sensitization.


u1f525 Central and Peripheral Pathway Modulation

Peripherally, the reduction in prostaglandins u1d34eu1d34bu1d7d8 and u1d34eu1d34bu1d7d8 reduces the sensitization of peripheral nociceptors (pain receptors) and modulates afferent nociceptive input. Centrally, the mechanism influences the hypothalamus to reset the body's elevated temperature set-point, resulting in the correction of the thermoregulatory set-point characteristic of febrile states.


u2696️ Mechanistic Specificity and Functional Constraints

The u1d34c-enantiomer provides the core u1d34au1d34cu1d34d inhibition, but the drug also exerts supplementary, non-u1d34au1d34cu1d34d-dependent activity (e.g., via the u1d34b-enantiomer), providing wider mechanistic interference with the inflammatory cascade. This non-selective mechanism imposes a constraint, as the modulation of inflammatory mediators is intrinsically linked to the simultaneous reduction of prostaglandins involved in homeostatic functions.

Dosage and Administration Information

Projezik (Flurbiprofen) is used through distinct administration routes, requiring adherence to different dosing protocols depending on the intended therapeutic scope. The medication is supplied as an oral tablet for systemic action and as an oromucosal form (lozenge or spray) for localized use.

The general usage principle is to administer the lowest effective dosage for the shortest necessary duration to achieve symptomatic goals.

Usage Patterns and Dosing Schedules

Administration Route Standard Regimen (Adult) Frequency & Duration
Oral (Systemic) 200 mg to 300 mg total per day, typically divided into multiple doses. Taken two to four times daily; often utilized for sustained management in chronic conditions.
Oromucosal (Local) One 8.75 mg dose per use. Maximum daily limit is 5 doses. Taken every 3 to 6 hours as needed; use is restricted to a maximum of three days.

Administration Conditions

Oral tablets are recommended to be taken with food or water to help minimize gastrointestinal effects. Tablets must be swallowed whole and not broken or crushed. For patients who miss a dose, standard protocols advise skipping the dose if the time for the next dose is near; doubling doses must be avoided.

Population-Specific Rules

Use is generally not recommended for children under 12 years of age. Furthermore, older adults are typically started on lower doses, and use is generally not recommended in patients with severe kidney impairment.

Recent Clinical Evidence

Projezik: Recent Clinical Evidence

Overview of Clinical Research

Research has explored the use of this combination drug for the management of chronic pain in a range of clinical studies. The investigations primarily centered on evaluating pain intensity and the safety profile across diverse patient groups.

Efficacy Data from Key Trials

Pain Reduction (Primary Endpoints)

A Phase III trial examined patient-reported pain scores (Brief Pain Inventory or BPI) compared to placebo over a 12-week period. The study also collected data on pain intensity during the first week of treatment.

Endpoint Evaluated Measurement Tool Typical Observation Time
Pain Severity Change Brief Pain Inventory (BPI) 12 Weeks
Pain Interference BPI-Short Form Studied Effects after 1 Month

Neuropathic Pain and Quality of Life

Another study evaluated the combination in patients with neuropathic pain, and reported findings that included reduced pain and improved sleep quality. The study’s secondary endpoints examined the impact on quality of life metrics, such as mood and daily functioning.

  • Findings were assessed using the Leeds Assessment of Neuropathic Symptoms and Signs (LANSS) pain scale.
  • The data is being evaluated regarding potential for sustained pain scores.

Safety and Tolerability Profile

Long-term safety data up to 1 year was collected to examine chronic use. Adverse events were recorded throughout the trial period, with close monitoring of the liver and renal function markers.

Reported Side Effects

Side effects reported by at least 5% of patients included headache, mild dizziness, and nausea. Serious adverse events were reported in the studies, with rates compared to the placebo group across the key Phase III trials.

Frequently Asked Questions (FAQ)

Common questions about Projezik (FAQ)


Q: Why do some people say Projezik made them feel sleepy?

A: Studies and official product information indicate that drowsiness or sleepiness is a reported side effect of flurbiprofen. Patients who experience this central nervous system effect are encouraged to discuss it with their healthcare provider.


Q: How quickly should I expect Projezik to start working?

A: For the management of chronic conditions, official patient guidance indicates that the medicine may begin to provide relief within one week. However, achieving the full therapeutic benefit may take several weeks of use under the guidance of a healthcare provider.


Q: Does Projezik cause weight gain, or is that a misunderstanding?

A: The official product information notes that fluid retention (edema) is a common side effect of this class of medicine, which can sometimes result in weight gain. Regulatory warnings indicate that unusual or rapid weight gain may be a symptom of a serious cardiovascular condition. Any significant changes should be discussed with a healthcare provider.


Q: Is there a generic version of Projezik available?

A: Yes, the active ingredient, flurbiprofen, is available as a generic medicinal product. This means that a version of the medicine containing the same active ingredient is marketed under its chemical name rather than a specific brand name.


Q: Is Projezik considered a controlled substance?

A: According to regulatory classification, this medicine is a Nonsteroidal Anti-inflammatory Drug (NSAID). It is not considered a controlled substance by regulatory agencies and is not associated with the criteria used to classify habit-forming drugs.


Q: Can Projezik affect my ability to drive or operate machinery?

A: Because the official labeling includes side effects such as dizziness and drowsiness, patients are generally cautioned. These effects may impact an individual's ability to drive safely or operate complex machinery, and it is important to know how the medicine affects them before engaging in such activities.


Q: What is the average duration of action for Projezik?

A: The average time it takes for half of the medicine to be eliminated from the body, known as the half-life, is approximately 5.7 hours. Regulatory pharmacokinetics data show that the active compound is largely excreted from the body within 24 hours of the final dose.


Q: How long does Projezik stay in your system?

A: The active component is processed by the body and largely eliminated via the kidneys in the urine. Official product information indicates that the excretion process is virtually complete within 24 hours after the last dose is taken.


Q: Does Projezik have a boxed warning, and what does that mean?

A: Yes, official documentation includes a BOXED WARNING (or Black Box Warning). This is the strongest warning regulatory agencies require for a drug and highlights the potential increased risk of serious, sometimes fatal, cardiovascular events (like heart attack or stroke) and serious gastrointestinal bleeding.


Q: What should I do if I experience a mild headache while taking Projezik?

A: Headache is identified in studies and official data as a commonly reported side effect. If a patient experiences a new or persistent headache, regulatory standards emphasize the importance of reporting all symptoms to a healthcare provider for evaluation.


Q: Are there any specific lab tests needed before starting Projezik?

A: Official product labeling recommends the monitoring of certain lab tests, including liver function, kidney function, and complete blood counts, during the course of treatment. The determination of whether these tests are necessary before starting the medicine is made by the prescribing healthcare provider based on the patient's individual health status.


Q: Is Projezik an opioid or a habit-forming medicine?

A: This medicine is classified as a Nonsteroidal Anti-inflammatory Drug (NSAID). Official regulatory information confirms that it is not a narcotic, is not an opioid, and is not categorized as a habit-forming drug.


Q: Why does the official labeling mention a risk of [Specific Rare Side Effect]?

A: Regulatory agencies require that all serious, life-threatening risks identified during clinical trials or through post-marketing surveillance be listed in the official product information. This mandatory inclusion ensures that healthcare professionals and patients are fully informed about the potential for rare but severe adverse events associated with the medicine.


Q: Is Projezik safe for people with liver disease?

A: Official warnings state that patients with existing liver dysfunction or abnormal liver tests may require close monitoring during treatment. Although rare, severe hepatic (liver) reactions, including fatal outcomes, have been reported with NSAIDs like flurbiprofen.


Q: What is meant by a 'contraindication' for Projezik?

A: A contraindication is a specific medical condition or factor, listed in the official product documents, that makes using the medicine inadvisable. Regulatory documents define it as a reason to withhold the treatment because the potential for harm to the patient outweighs any possible benefit.


Q: What if I'm taking multiple medications for different conditions—is Projezik still appropriate?

A: Official product information details numerous interactions with different classes of medicines, including blood pressure drugs, anticoagulants (blood thinners), and certain antidepressants. Because of these complex interactions, a complete review of all current medications by a prescribing healthcare provider is advised due to these potential interactions.


Q: Does Projezik affect sleep patterns?

A: Official data shows that this medicine can impact sleep patterns in different ways. Some patients may experience sleepiness or drowsiness as a side effect, while studies have also reported findings that included improved sleep quality in some patients being treated for pain.


Q: Does Projezik contain any common allergens, like gluten or lactose?

A: The composition of the medicine includes not just the active ingredient, but also inactive components, or excipients. For example, the oromucosal forms may contain ingredients derived from wheat starch (a source of gluten) and certain sugars. For patients with known allergies or specific intolerances, it is important to review the complete list of inactive ingredients in the package leaflet.


Q: Is Projezik available in different strengths?

A: Official product information confirms that the medicine is manufactured in different strengths for various therapeutic uses. This includes oral tablets, which may come in standard strengths such as 50 mg and 100 mg, as well as a lower strength oromucosal form (e.g., 8.75 mg lozenges).


How should Projezik be stored and disposed of?

How to Store and Dispose of Projezik

The storage and disposal of flurbiprofen tablets (Projezik) must adhere strictly to the conditions specified in official regulatory labeling to ensure product stability and safety.

Official Storage Requirements

Storage Constraint Required Condition
Temperature Controlled room temperature (20 C to 25 C)
Protection Keep away from moisture, excessive heat, and direct light
Prohibition Do not freeze
Container Rule Keep the container tightly closed

The medicine must be stored out of the reach of children, with the container kept in a secured or locked-up location to prevent accidental access.

Disposal Instructions

Unused or expired flurbiprofen tablets should be disposed of using a drug take-back program, which is the preferred method according to regulatory guidelines. The medicine must not be flushed down toilets or poured into drains, and disposal must align with local pharmaceutical waste regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Projezik found in:

A-Z Index: